Source: International Congress 2016 – Mesothelioma and pleural disease: from the bench to the bedside
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Fabian Mairinger (Essen, Germany), Robert Fred Henry Walter, Claudia Vollbrecht, Daniel Christian Christoph, Kurt Werner Schmid, Jens Kollmeier, Helmut Hans Popper, Thomas Mairinger, Fabian Mairinger. Folic acid phenotype (FAP) as superior marker to predict pemetrexed response in pleural mesothelioma. Eur Respir J 2016; 48: Suppl. 60, 498

Member's Comments

No comment yet.

Related content which might interest you: Poor prognostic factors in advanced pulmonary adenocarcinoma patients receiving first-line gefitinib Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Gefitinib versus erlotinib as first-line treatment in EGFR mutant advanced lung adenocarcinoma Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Maintenance therapy with pemetrexed in non-small-cell lung cancer: Impact on survival Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Oncogenic drivers (OD) and matched targeted agents (TA): Impact on overall survival in patients with lung adenocarcinoma (LA)? Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 A randomised trial of active symptom control (ASC) with or without chemotherapy (CT) in the treatment of patients with malignant pleural mesothelioma. First results of the Medical Research Council/British Thoracic Society MS01 trial Source: Annual Congress 2007 - Pleural malignancy Year: 2007 Gene therapy with DDMC-p53 with or without cisplatin and microwave ablation. A future concept for local treatment in lung cancer Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Systemic treatment of malignant mesothelioma Source: Eur Respir Mon; 2009: 44: 419–434 Year: 2009 Ifosfamide (IFO) is a valuable alternative to cisplatin (CDDP) for first-line chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC): A meta-analysis Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013 Pleurodesis for malignant pleural effusions: A comparison of bleomycin or tranexamic acid alone versus a combination of both Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies Year: 2013 Pemetrexed in maintenance therapy of 164 patients with advanced non-small-cell lung cancer (NSCLC) Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 The prognostic value of D-dimer in lung carcinoma Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Locally advanced stage nonsmallcell cancers explode in hyperglisemia: A new prognostic factors? Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Clinical and therapeutic characteristics of patients died due to radiation-induced pneumonitis Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Elevated survivin is associated with a reduced survival in patients with malignant pleural effusion Source: Annual Congress 2013 –Fundamental biology of malignant pleural effusions Year: 2013 Prognostic factors for survival in lung cancer Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Early response detection in systemic lung cancer treatment using cell-free methylated SHOX2 (mSHOX2) plasma DNA Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015 Blood-staining of pleural fluid is an inaccurate predictor of pleural malignancy Source: International Congress 2015 – Malignant pleural effusions and mesothelioma Year: 2015 Site of first progression (PR) differs between stage III NSCLC patients treated with simultaneous radiochemotherapy (RTCT) and those treated with radiotherapy (RT) alone following induction chemotherapy (CT) Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014 Treatment with low-dose everolimus in patients with sporadic lymphangioleiomyomatosis (LAM) Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014